Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals reported consolidated revenue from operations of Rs. 1,710.72 crore for Q1 FY26, up about 9.5% from Rs. 1,561.73 crore in the same quarter last year. Consolidated profit after tax (after non-controlling interests) rose to Rs. 154.38 crore from Rs. 134.71 crore, a growth of roughly 14.6%, with EPS at Rs. 7.85 vs Rs. 6.84. The standalone picture was weaker: standalone revenue was almost flat at Rs. 1,494.17 crore (vs Rs. 1,475.56 crore), while standalone profit after tax fell sharply to Rs. 103.52 crore from Rs. 176.19 crore, with standalone EPS dropping to Rs. 5.27 from Rs. 8.96. Operating (EBITDA) margin on a consolidated basis improved to 16.84% from 15.32% a year ago, and net profit margin widened to 9.02% from 8.61%. The auditor's review report (KC Mehta & Co LLP) is unqualified on both consolidated and standalone numbers. Debt-equity ratio stood at a comfortable 0.22, and net worth crossed Rs. 5,349 crore on a consolidated basis.
The consolidated results show steady mid-teens profit growth and margin expansion, which is positive for shareholders. However, the sharp standalone PAT drop suggests that subsidiaries/joint ventures drove most of the gains, while the parent entity's profitability was squeezed—something investors may want to dig into. Overall, a stable quarter with no red flags from the auditor and a healthy balance sheet.